Antimicrobial activity of silver proteinate and its changes during storage



如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Against the background of antibiotic resistance problems, the choice of drugs with nonspecific antimicrobial action is an urgent solution in the treatment of upper respiratory tract infections. Silver proteinate, which has antimicrobial activity, is used as an active current ingredient in medical preparations.

AIM: To study the effect of the duration and temperature of storage of a medicinal product with the international nonproprietary name Silver proteinate on its antimicrobial activity.

MATERIALS AND METHODS: To perform a experimental study, reference strains of Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 9027), Bacillus cereus (ATCC 14579), Candida albicans (ATCC 10231), and silver proteinate solutions stored at 22 °C and 7 °C were taken as test cultures. The crops were carried out from the "zero" to the 75th day with an interval of 7 days. The antimicrobial activity was assessed by comparing the diameters of the growth suppression zones of microbial strains (mm) in the dynamics of the experiment.

RESULTS: On the 30th day of the study, the diameters of the growth suppression zones at 7 °C were larger: in S. aureus — by 25.0% (p=0.033), E. coli — by 12.2% (p=0.041), P. aeruginosa — by 18.3% (p=0.042), B. cereus — by 10.0% (p=0.005), C. albicans — by 42.7% (p=0.016). On the 37th, 45th, 53rd, 60th, 68th and 75th days of the study, the diameters of S. aureus, P. aeruginosa, B. cereus and C. albicans did not change (9, 8 and 7 mm, respectively); E. coli — by 37On the 30th, 45th, 53rd, and 60th, the diameters also did not change (8 mm) compared to the 30th day of the study, and on the 68th and 75th days, a decrease in the diameter of the growth suppression zone to 7 mm (12.5%, p=0.005) was noted.

CONCLUSIONS: Storage at 7 °C for 30 days does not reduce antimicrobial activity, allowing you to choose a convenient storage option for the working solution. Given the preservation of the antimicrobial activity of silver protein until day 75, its use in superinfection, as well as in the treatment of chronic forms of rhinosinusitis, can be recommended.

全文:

受限制的访问

作者简介

Elena Kotelevets

Ryazan State Medical University, Ryazan, Russia

Email: kotelevetse@mail.ru
ORCID iD: 0000-0001-7972-5861
SPIN 代码: 1609-1183
Scopus 作者 ID: 57215587895
Researcher ID: V-5975-2018

Cand. Sci. (Medicine) , Assistant Professor of the Department of Microbiology

俄罗斯联邦, Ryazan, Russia

Irina Vorobyova

Ryazan State Medical University, Ryazan, Russia

Email: francais64@mail.ru
ORCID iD: 0000-0002-9113-9184
SPIN 代码: 9216-5887

Cand. Sci. (Biology), Assistant Professor, Assistant of the Department of Microbiology

俄罗斯联邦, Ryazan, Russia

Valery Kiryushin

Ryazan State Medical University, Ryazan, Russia

编辑信件的主要联系方式.
Email: v.kirushin@rzgmu.ru
ORCID iD: 0000-0002-1258-9807
SPIN 代码: 2895-7565

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Ryazan, Russia

参考

  1. Burmistrov VA, Zaikovsky VI, Burmistrov AV, et al. Comparative electron microscopic and microbiological examination of silver proteinate preparations. Siberian Scientific Medical Journal. 2018;38(4):30–36. (In Russ.) doi: 10.15372/SSMJ20180404
  2. Kiselyov B, Abdulkerimov HT, Terskova NE, Chaukina VA. Clinical efficacy of the drug 200 mg silver proteinate in the complex therapy of acute infectious rhinitis in children, which occurred as part of an acute respiratory infection. Russian Otorhinolaryngology. 2021;20(4):88–95. doi: 10.18692/1810-4800-2021-4-88-95
  3. Karpishchenko SA, Rodneva YuA, Ekushov KA. Improving the clinical effectiveness of the treatment of acute inflammatory diseases of the upper respiratory tract in children with the use of silver-based medicines. Medical Council. 2022;(19):42–52. doi: 10.21518/2079-701X-2022-16-19-42-52
  4. Gurov AV, Ermolaev AG, Dubovaya TK, et al. Current possibilities of using silver proteinate in the treatment of inflammatory diseases of the nose and paranasal sinuses. Medical Council. 2023;(7):46–51. doi: 10.21518/ms2023-120
  5. Wise SK, Lin SY, Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis—executive summary. Int Forum Allergy Rhinol. 2018;8(2):85–107. doi: 10.1002/alr.22070
  6. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. Int Forum Allergy Rhinol. 2023;13(4):293–859. doi: 10.1002/alr.23090
  7. Khina AG, Krutyakov YuA. Similarities and differences in the mechanism of antibacterial action of silver ions and nanoparticles. Applied Biochemistry and Microbiology. 2021;57(6):523–535. doi: 10.31857/S0555109921060052
  8. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213–739. doi: 10.1002/alr.22741
  9. Cheng M, Dai Q, Liu Z, et al. New progress in pediatric allergic rhinitis. Front. Immunol. 2024;15:1452410. doi: 10.3389/fimmu.2024.1452410
  10. Wang J, Zhang Y, Chen Y, et al. Risk factors investigation for different outcomes between unilateral and bilateral chronic rhinosinusitis with nasal polyps patients. Clin Transl Allergy. 2024;14(9):e12395. doi: 10.1002/clt2.12395
  11. Zaitoun F, Al Hameli H, Karam M, et al. Management of Allergic Rhinitis in the United Arab Emirates: Expert Consensus Recommendations on Allergen Immunotherapy. Cureus. 2024;16(7):e65260. doi: 10.7759/cureus.65260
  12. Norman G, Christie J, Liu Z, et al. Antiseptics for burns. Cochrane Database Syst Rev. 2017;7(7):CD011821. doi: 10.1002/14651858.CD011821.pub2
  13. Fung MC, Bowen DL. Silver products for medical indications: risk-benefit assessment. J Toxicol Clin Toxicol. 1996;34(1):119–26. doi: 10.3109/15563659609020246
  14. Yan X, He B, Liu L, et al. Antibacterial mechanism of silver nanoparticles in Pseudomonas aeruginosa: proteomics approach. Metallomics. 2018;10(4):557–564. doi: 10.1039/c7mt00328e
  15. Slawson RM, Lohmeier-Vogel EM, Lee H, Trevors JT. Silver resistance in Pseudomonas stutzeri. Biometals. 1994;7:30–40. doi: 10.1007/BF00205191
  16. Liao S, Zhang Y, Pan X, et al. Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant Pseudomonas aeruginosa. Int J Nanomedicine. 2019;14:1469–1487. doi: 10.2147/IJN.S191340
  17. Jung WK, Koo HC, Kim KW, et al. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl Environ Microbiol. 2008;74(7):2171–2178. doi: 10.1128/aem.02001-07
  18. Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ. Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria. Sci Transl Med. 2013;5(190):190ra81. doi: 10.1126/scitranslmed.3006276
  19. Rugerio-Vargas C, Hurtado MM. Modification of the Silver Proteinate Impregnation Technique for Protozoa and Cultured Nerve Cells. Biotechnic & Histochemistry. 1991;66(3):131–135. doi: 10.3109/10520299109110566
  20. Bozhkova SA, Gordina EM, Markov MA, et al. The Effect of Vancomycin and Silver Combination on the Duration of Antibacterial Activity of Bone Cement and Methicillin-Resistant Staphylococcus aureus Biofilm Formation. Traumatology and Orthopedics of Russia. 2021;27(2):54–64. doi: 10.21823/2311-2905-2021-27-2-54-64
  21. Xu L, Wang YY, Huang J, et al. Silver nanoparticles: Synthesis, medical applications and biosafety. Theranostics. 2020;10(20):8996–9031. doi: 10.7150/thno.45413
  22. Abdalla SSI, Katas H, Azmi F, et al. Antibacterial and Anti-Biofilm Biosynthesised Silver and Gold Nanoparticles for Medical Applications: Mechanism of Action, Toxicity and Current Status. Curr Drug Deliv. 2020;17(2):88–100. doi: 10.2174/1567201817666191227094334
  23. Hempelmann E, Krafts K. The mechanism of silver staining of proteins separated by SDS polyacrylamide gel electrophoresis. Biotech Histochem. 2017;92(2):79–85. doi: 10.1080/10520295.2016.1265149
  24. Wong AYH, Xie S, Tang BZ, Chen S. Fluorescent Silver Staining of Proteins in Polyacrylamide Gels. J Vis Exp. 2019;(146). doi: 10.3791/58669-v

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © ,

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС 77 - 86785 от 05.02.2024 (ранее — ПИ № ФС 77 - 59057 от 22.08.2014).